CEConversations

Latest Episodes:

Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1 Aug 06, 2026

Show notes

Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in longitudinal patient care. Despite recent advances, including updated diagnostic criteria and expanded use of mitogen-activated protein kinase kinases (MEK) inhibitors for both pediatric and adult patients, oncology nurses often demonstrate gaps in knowledge, confidence, and competence in recognizing NF1-associated plexiform neurofibromas (PNs), monitoring for malignant transformation, and supporting treatment decision-making. The heterogeneity of NF1 manifestations, the risk of serious complications such as malignant peripheral nerve sheath tumors (MPNST), and the need for coordinated, multidisciplinary care further underscore the importance of specialized, evidence-based education.

In this enduring Creative Educational Concepts (CEC) Oncology Nursing Society (ONS) chapter installment, expert faculty will assist learners to combine NF1 diagnostic and treatment guidelines for early recognition of NF-PNs, incorporate MEK inhibitors using evidence-based safety and management strategies in adult and pediatric patients, and develop interprofessional, patient-centered care plans that support individualized, longitudinal management.

Learn More Here

A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC Jul 01, 2026

Show notes

Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell lung cancer (mNSCLC). Despite their growing impact, the mechanisms behind ADCs remain unclear for many clinicians and multidisciplinary care teams. At the same time, the expanding use of immuno-oncology (IO) therapies in mNSCLC has introduced overlapping toxicity profiles that can obscure the identification and management of ADC-related adverse events. To confidently navigate this evolving landscape, clinicians need best-in-class education that demystifies ADC mechanisms, translates clinical trial and biomarker data into actionable patient selection strategies, and differentiates safety profiles to optimize care for patients with mNSCLC.

In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.

Learn More Here

Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies Jul 01, 2026

Show notes

Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role of biomarker-driven therapies, and the need to proactively manage treatment-related toxicities all require ongoing clinical integration to support patient safety and continuity of care. Concurrently, inequities persist in access to molecular testing, novel therapies, and clinical trials, underscoring the need for refined interprofessional, patient-centered approaches that promote equitable access, reduce disparities, and enhance patient education to optimize outcomes.

In this CE Concepts recorded webcast, expert faculty will review recent developments in the management of advanced or recurrent EC, with a focus on applying emerging clinical evidence, integrating biomarker-driven therapies, and addressing treatment-related toxicities. This program will further explore strategies to enhance interprofessional collaboration, support equitable access to molecular testing and novel therapies, and strengthen patient-centered education to optimize care delivery.\

Learn More Here

Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN Jul 01, 2026

Show notes

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity due to pain, disfigurement, neurologic impairment, and risk of malignant transformation. Despite advances in understanding NF1 biology, care remains complex and often fragmented across specialties, leading to delayed recognition and limited access to evolving therapies. Recent clinical evidence has established MEK inhibitors as targeted therapeutic options for NF1-associated PNs. Incorporating these therapies into practice requires careful patient selection, safety monitoring, and interprofessional coordination to ensure optimal outcomes.

This CEC Oncology recorded symposium will address these critical gaps by equipping neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, advanced practitioners, and nurses with strategies for early recognition of NF1-associated tumors, effective integration of MEK inhibitors, and development of evidence-based, interprofessional care plans that support individualized, longitudinal management.

Learn More Here

Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors Jul 01, 2026

Show notes

Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues to impact patient quality of life. Subcutaneous (SC) administration represents the next step in patient-centered innovation, offering comparative efficacy and safety to traditional intravenous (IV) infusions with shorter chair times, greater comfort, and expanded access for patients in underserved communities. By adopting SC delivery, oncology teams can empower patients with greater autonomy and redefine compassionate care through streamlined system integration. Collaboration among clinicians, nurses, and pharmacists ensures that every patient can play a more active role in their treatment journey.

In this CE Concepts Snack, expert faculty and a patient living with cancer share real-world insights into the transition from IV to SC immunotherapy. Through clinical evidence and practical discussion, this program highlights strategies for integrating approved SC formulations and improving the patient experience across practice settings.

Learn More Here

The New Era of Hemophilia Treatment Jan 28, 2026

Show notes

We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health, mental health, aging, and everyday habits that protect long‑term outcomes.
• Non‑factor prophylaxis versus factor replacement and what each does best
• Treating beyond dated trough targets toward durable thrombin generation
• Matching therapy to activity level, joint status, and venous access
• Why shared decision making beats one‑size‑fits‑all regimens
• Practical plans for breakthrough bleeds and procedures
• Aging, comorbidities, and proactive screening for liver cancer and heart disease
• Weight, movement, physical therapy, and joint load reduction
• Vitamin D, bone health, and osteoporosis risk
• Chronic pain, anxiety, and skills to break rumination with breathwork
• Caregiver choices for kids and the importance of evolving plans

This webisode series will provide a review of non-factor prophylaxis therapies for patients with hemophilia A or B with or without inhibitors, as well as provide helpful insights on the roles of gene therapies, considering safety profiles and monitoring requirements, aligning treatment options with lifestyle and individual preferences, and how bleed plans change with the different prophylaxis therapies. These webisodes intend to help patients feel more prepared to engage the hemophilia care team in meaningful conversations that support shared decision-making in treatment planning: https://cmeo.me/PE-020

MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management Oct 01, 2025

Show notes

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings.

In this CEC Oncology live, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.

Learn More: https://www.ceconcepts.com/activity/save-the-date-mek-inhibitors-in-neurofibromatosis-type-1-nursing-contributions-to-nf1-pn-management/

Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies Sep 19, 2025

Show notes

| Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying early signs of DTs, understanding novel systemic therapies like tyrosine kinase and gamma-secretase inhibitors, and managing their distinct adverse event (AE) profiles. As frontline providers in symptom management and patient counseling, these clinicians urgently need education on evidence-based strategies for monitoring and mitigating treatment-related toxicities. Targeted learning will empower nursing professionals to improve patient safety, support adherence, and deliver comprehensive, individualized care across the DT treatment continuum. In this CE Concepts recorded symposium, expert faculty will guide learners to identify features and challenges of early diagnosis and treatment of DTs, evaluate the use of novel targeted therapies, and implement evidence-based strategies to monitor and manage AEs associated with systemic therapies for DTs to improve patient safety and adherence.

Learn More:https://www.ceconcepts.com/activity/desmoid-tumors-in-focus-early-recognition-evolving-therapies-and-nursing-led-care-strategies-2/

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations Sep 19, 2025

Show notes

| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging clinical trial data into everyday practice, particularly in identifying candidates for mitogen-activated protein kinase inhibitors, managing adverse events, and coordinating multidisciplinary care. Limited experience with NF1 further contributes to gaps in long-term disease monitoring and personalized treatment planning. To close these gaps, clinicians must be equipped with practical, case-based strategies to improve early disease recognition, evidence-based management, and interprofessional collaboration that includes a team-based approach to address both clinical and psychosocial needs in the journey of patients with NF1. In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

Learn More: https://www.ceconcepts.com/activity/the-mektrix-decoding-the-real-world-impact-of-therapeutic-advances-in-neurofibromatosis-type-1-associated-plexiform-neurofibroma-management-across-pediatric-and-adult-populations-2/

Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events Aug 28, 2025

Show notes

As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutionized the treatment of hematological malignancies, they are also associated with symptoms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infection, and cardiotoxicity. While most cases of CRS and neurotoxicity are self-limiting and only require supportive care, some patients can progress to needing ICU care. To address these risks, EM clinicians require education on the relationship of MOAs of T-cell-directing therapies to potential AEs and improve their confidence and competence in diagnosing and treating CRS, neurotoxicity, and other toxicities associated with these agents in emergency settings. In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS.

Learn More: https://www.ceconcepts.com/activity/emergency-care-of-patients-with-cancer-receiving-car-t-cell-and-bispecific-antibody-immunotherapies-experiencing-serious-adverse-events/

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected

Our TOPPODCAST Picks

Follow Us

Stay Connected

CEConversations

Related Podcasts

1

2

3

4

5

6